A year ago, I thought that Genworth (NYSE:GNW) was a high-risk insurance story that was trading at a substantial discount to its long-term value. With the stock up almost 130% since then, I feel pretty good about that call. Looking at the company again today, though, I'm not nearly as optimistic about the stock. While the stock is still undervalued on a long-range ROE model, the growing challenges in mortgage insurance and long-term care insurance bode poorly for nearer-term value creation.
U.S. Mortgage Insurance Profitable Again … But Will It Last?
One of the relatively few bright spots in Genworth's first quarter results was the return of the U.S. mortgage insurance business to profitability. Prices for insurance have been improving recently, and the U.S. housing market has been looking better. While that was a nice result, I'm sorely concerned that it will not last.
On the whole, I don't think the company has huge legacy issues to worry about, but competition is a different story. Radian (NYSE:RDN) and MGIC (NYSE: MTG) have recapitalized with the intention of writing more business (and near 52-week highs), and the outlook for better rates has led Arch Capital (Nasdaq: ACGL) to get into the business through its acquisition of CMG. With NMI Holdings also writing policies again, the U.S. mortgage insurance market is getting more crowded and I don't see how this is a good thing for Genworth. 
Long-Term Care Is Under Pressure
With the exit of MetLife (NYSE:MET), Prudential (NYSE:PRU), and Unum (NYSE:UNM) from the market, Genworth is far and away the largest underwriter in long-term care insurance with more than one-third of the market. Unfortunately, I'm of the opinion that when a well-run insurance company like MetLife decides to get out, it doesn't say a lot of good things about the companies left behind.
SEE: Investing In Health Insurance Companies

To that end, reserve deficiencies in the LT care market are getting a lot worse. Low interest rates are certainly hurting, but so too is greater than forecast loss severity. Genworth is looking to respond with steep rate increases (as much as 50% over the next three to five years in some cases), but it sounds as though that's only going to allow older blocks to reach breakeven. The company is also looking to start capping benefits, but it's unclear if regulators will sign-off on this and/or whether Genworth will lose business to rivals like CNO Financial (NYSE:CNO) and Manulife (NYSE:MFC).
Life Insurance Pressured
Life insurance is still a meaningful business for Genworth, but this too is not doing particularly well. A lot of the trouble can be tied to the low rate environment, but I think Genworth is also just not as good at underwriting or running a life insurance business as MetLife. Consequently, while higher rates would definitely help the business, I think it's going to be hard for the company to achieve “industry standard” returns over the long term.
The Bottom Line
Genworth isn't nearly as appealing today as it was a year ago. I do believe the company may have to shore up the long-term care business, and I think management may find it harder to pass through the rate increases than they currently believe (though lapse rates have been low, and could stay low on the uncapped policies). What's more, I do believe that increased competition in the mortgage insurance market is going to squeeze the company – if I have to place a bet between Arch Capital and Genworth, I'm betting on Arch Capital winning.
Valuation on Genworth shares is pretty mixed today. Using a long-term return on equity model, I believe Genworth can attain long-term ROEs of 7.5%, and that works out to about $16 per share today. Looking at tangible book relative to returns on equity and assets, though, I think Genworth's industry-low returns merit a sharp discount to tangible book value. In essence, I believe that the company's returns are running close to half the cost of equity, meaning that the company is destroying economic value. Accordingly, looking at a long-term regression analysis of the industry suggests that the appropriate multiple is 0.5x, leading to a $11.60 target/fair value.
SEE: The Value Investor's Handbook

If you belief that stronger housing demand will keep mortgage insurance rates up even in the face of competition, I suppose there's an argument for hanging on to Genworth shares. Between the entry of new mortgage insurance rivals and worsening conditions in long-term care insurance, though, I think Genworth is a better source of funds than a destination for them.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Products and Investments

    Cash Value vs Term Life Insurance: Which is Best?

    The debate between cash value life insurance and term insurance plus an investment plan is an ongoing one. Here's a look at both sides of the argument.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  7. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  8. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  9. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  10. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  1. Do beneficiaries pay taxes on life insurance?

    Generally speaking, when the beneficiary of a life insurance policy receives the death benefit, this money is not counted ... Read Full Answer >>
  2. Can I borrow from my annuity to put a down payment on a house?

    You can borrow from your annuity to put a down payment on a house, but be prepared to pay an assortment of fees and penalties. ... Read Full Answer >>
  3. What are the biggest disadvantages of annuities?

    Annuities can sound enticing when pitched by a salesperson who, not coincidentally, makes huge commissions selling them. ... Read Full Answer >>
  4. What are the risks of annuities in a recession?

    Annuities come in several forms, the two most common being fixed annuities and variable annuities. During a recession, variable ... Read Full Answer >>
  5. How can I determine if a longevity annuity is right for me?

    A longevity annuity may be right for an individual if, based on his current health and a family history of longevity, he ... Read Full Answer >>
  6. Can your life insurance company sue you?

    A life insurance company generally cannot sue you, but it can sue your estate. The company may do this in order to recover ... Read Full Answer >>
Trading Center